Last reviewed · How we verify
Perfluoropentane (PERFLENAPENT)
At a glance
| Generic name | PERFLENAPENT |
|---|---|
| Drug class | perflenapent |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1998 |
Approved indications
Common side effects
Key clinical trials
- Novel Oxygen Therapeutic NanO2 for Mild Respiratory Distress in Phase 1b (Phase 1)
- A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme (Phase 1)
- A Phase Ib/II Dose-finding Study of DDFPe in Patients With Acute Ischemic Stroke (Phase 1)
- A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE (Phase 2)
- Phase IIb to Restore Oxygen in Large Vessel Occlusion Patients En Route for MT Using NanO2 (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perfluoropentane CI brief — competitive landscape report
- Perfluoropentane updates RSS · CI watch RSS